I can't imagine that we could find any new formulation of bisantrene that is so significantly better than RC220 that we would want to change. RC220 does everything that we could want from a IV formulation - solves the precipitation problem and provides the exact same drug metabolism and excretion (PK/PD) profile as the original RC110. From all the animal studies we have done, RC220 is basically identically to RC110 once in the body except for the precipitation problem. Given the precipitation problem is caused by an identical process (pH) in animals and humans I am as confident as I can be that RC220 will work the same way in humans.
Even if we were to develop say an oral version of bisantrene, this would not be a substitute for an IV formulation and we would have two independent formulations that are of value. Having different formulations for different clinical applications is very common in the pharmaceutical industry and it only adds value.
RAC - Charts & Price Action, page-18420
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |